Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695500 vs Rituximab in Low Tumor Burden Follicular Lymphoma
NCT02417129Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2015
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of MabionCD20 in follicular lymphoma (FL), sponsored by Boehringer Ingelheim. Started Apr 2015; status: terminated.
02
Drugs
MabionCD20
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02417129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02417129.